Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.7% - Here's Why

Key Points

• Dyne Therapeutics' shares fell 4.7% during trading on Monday, closing at $12.44, with trading volume decreasing by 26% compared to the average session volume.
• Research analysts have mixed ratings on the stock, with three analysts issuing a Strong Buy rating while Weiss Ratings restated a "sell (d-)" rating, contributing to the stock's volatility.
• CEO John Cox significantly increased his stake by purchasing 100,000 shares at an average price of $9.11, indicating confidence in the company's future prospects.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price fell 4.7% during trading on Monday . The stock traded as low as $12.44 and last traded at $12.44. 1,932,025 shares changed hands during trading, a decline of 26% from the average session volume of 2,598,925 shares. The stock had previously closed at $13.06.

Wall Street Analyst Weigh In

DYN has been the topic of several recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Dyne Therapeutics in a research report on Saturday, September 27th. Chardan Capital lowered their price target on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a report on Tuesday, July 29th. Raymond James Financial upgraded shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price target for the company from $31.00 to $35.00 in a research report on Monday, August 25th. JPMorgan Chase & Co. decreased their price objective on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. Finally, Sanford C. Bernstein began coverage on Dyne Therapeutics in a research report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $34.07.

Dyne Therapeutics Stock Down 3.1%

The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $12.47 and a two-hundred day simple moving average of $11.19. The company has a market cap of $1.80 billion, a PE ratio of -3.28 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO John Cox acquired 100,000 shares of the stock in a transaction on Monday, July 14th. The shares were bought at an average price of $9.11 per share, with a total value of $911,000.00. Following the completion of the purchase, the chief executive officer owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. This represents a 70.33% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.77% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently modified their holdings of the company. Graham Capital Management L.P. purchased a new position in Dyne Therapeutics during the first quarter worth about $651,000. Rhumbline Advisers lifted its holdings in Dyne Therapeutics by 4.2% in the first quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock valued at $1,398,000 after acquiring an additional 5,383 shares during the last quarter. Voleon Capital Management LP purchased a new position in Dyne Therapeutics in the first quarter worth approximately $624,000. GAMMA Investing LLC increased its stake in Dyne Therapeutics by 837.5% during the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after acquiring an additional 2,345 shares during the last quarter. Finally, Swiss National Bank raised its position in Dyne Therapeutics by 8.9% in the first quarter. Swiss National Bank now owns 118,300 shares of the company's stock valued at $1,237,000 after purchasing an additional 9,700 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.